Cargando…

The Characteristics of Natural Killer Cells in Chronic Hepatitis B Patients Who Received PEGylated-Interferon versus Entecavir Therapy

BACKGROUND: To explore the role of natural killer (NK) cells in the process of hepatitis B virus (HBV) clearance and whether their phenotype is related to antiviral treatment outcome in chronic hepatitis B (CHB) patients. METHOD: We performed a single-center prospective cohort study to analyze chang...

Descripción completa

Detalles Bibliográficos
Autores principales:	Cao, Weihua, Li, Minghui, Zhang, Lu, Lu, Yao, Wu, Shuling, Shen, Ge, Chang, Min, Liu, Ruyu, Gao, Yuanjiao, Hao, Hongxiao, Hu, Leiping, Yi, Wei, Pan, Calvin Q., Xie, Yao
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Hindawi 2021
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7857883/ https://www.ncbi.nlm.nih.gov/pubmed/33575322 http://dx.doi.org/10.1155/2021/2178143

Ejemplares similares

Changes of natural killer cells’ phenotype in patients with chronic hepatitis B in intermittent interferon therapy
por: Bi, Xiaoyue, et al.
Publicado: (2023)

The reduction in CD8(+)PD-1(+) T cells in liver histological tissue is related to Pegylated IFN-α therapy outcomes in chronic hepatitis B patients
por: Liu, Ruyu, et al.
Publicado: (2020)

Dynamic changes of cytokine profiles and virological markers during 48 weeks of entecavir treatment for HBeAg-positive chronic hepatitis B
por: Li, Minghui, et al.
Publicado: (2022)

Functional molecular expression of nature killer cells correlated to HBsAg clearance in HBeAg-positive chronic hepatitis B patients during PEG-IFN α-2a therapy
por: Cao, Weihua, et al.
Publicado: (2022)

Hepatitis B core-related antigen serum levels may be a predictor of acute flare of chronic hepatitis B among pregnant women in the immune-tolerant phase of chronic HBV infection after short-course antiviral therapy
por: Liu, Ruyu, et al.
Publicado: (2023)

A nomogram based on HBeAg, AST, and age to predict non-minimal liver inflammation in CHB patients with ALT <80 U/L
por: Zhang, Lu, et al.
Publicado: (2023)

Immune Mechanisms Underlying Hepatitis B Surface Antigen Seroclearance in Chronic Hepatitis B Patients With Viral Coinfection
por: Wu, Shuling, et al.
Publicado: (2022)

Cytokine profiles and CD8+ T cells in the occurrence of acute and chronic hepatitis B
por: Xie, Si, et al.
Publicado: (2022)

Dynamic changes of the proportion of HLA-DR and CD38 coexpression subsets on T lymphocytes during IFN-based chronic hepatitis B treatment
por: Lin, Yanjie, et al.
Publicado: (2023)

Postpartum hepatitis and host immunity in pregnant women with chronic HBV infection
por: Zhang, Lu, et al.
Publicado: (2023)

Effects of hepatitis B virus infection and strategies for preventing mother-to-child transmission on maternal and fetal T-cell immunity
por: Lu, Huihui, et al.
Publicado: (2023)

Add-on Pegylated Interferon Alpha-2a Therapy in Chronic Hepatitis B Japanese Patients Treated with Entecavir
por: Tamai, Hideyuki, et al.
Publicado: (2017)

Sustained viral response and relapse after discontinuation of oral antiviral drugs in HBeAg-positive patients with chronic hepatitis B infection
por: Sun, Fangfang, et al.
Publicado: (2022)

The efficacy of pegylated interferon alpha-2a and entecavir in HBeAg-positive children and adolescents with chronic hepatitis B
por: He, Yi, et al.
Publicado: (2022)

Study on liver histopathology of chronic HBV infected patients with different normal ALT values
por: Zeng, Zhan, et al.
Publicado: (2022)

The relation of the frequency and functional molecules expression on plasmacytoid dendritic cells to postpartum hepatitis in women with HBeAg-positive chronic hepatitis B virus infection
por: Wang, Fuchuan, et al.
Publicado: (2022)

Entecavir add-on or switch-to pegylated interferon improves HBsAg clearance in HBe antigen negative chronic hepatitis B patients
por: Yan, Lei, et al.
Publicado: (2018)

Study on pathological and clinical characteristics of chronic HBV infected patients with HBsAg positive, HBV DNA negative, HBeAg negative
por: Zeng, Zhan, et al.
Publicado: (2023)

Efficacy of Pegylated Interferon Monotherapy versus Sequential Therapy of Entecavir and Pegylated Interferon in Hepatitis B e Antigen-Positive Hepatitis B Patients: A Randomized, Multicenter, Phase IIIb Open-Label Study (POTENT Study)
por: Jun, Dae Won, et al.
Publicado: (2018)

Combination of Entecavir or Tenofovir with Pegylated Interferon-α for Long-Term Reduction in Hepatitis B Surface Antigen Levels: Simultaneous, Sequential, or Add-on Combination Therapy
por: Yoshida, Kanako, et al.
Publicado: (2021)

Comparison of Serum Hepatitis B Virus RNA Levels and Quasispecies Evolution Patterns between Entecavir and Pegylated-Interferon Mono-treatment in Chronic Hepatitis B Patients
por: Yu, Xiao-qi, et al.
Publicado: (2020)

Rescue use of Pegylated Interferon in Dialysis Patient who Failed to Respond Sofosbuvir
por: Katiyar, Harshita, et al.
Publicado: (2023)

Expression of Functional Molecule on Plasmacytoid Dendritic Cells Is Associated With HBsAg Loss in HBeAg-Positive Patients During PEG-IFN α-2a Treatment
por: Cao, Weihua, et al.
Publicado: (2022)

Low hepatitis B surface antigen and HBV DNA levels predict response to the addition of pegylated interferon to entecavir in hepatitis B e antigen positive chronic hepatitis B
por: Liem, Kin Seng, et al.
Publicado: (2019)

Kinetics of Hepatitis B Surface Antigen Level in Chronic Hepatitis B Patients who Achieved Hepatitis B Surface Antigen Loss during Pegylated Interferon Alpha-2a Treatment
por: Li, Ming-Hui, et al.
Publicado: (2017)

Obesity and hepatocellular carcinoma in patients receiving entecavir for chronic hepatitis B
por: Lee, Jaemin, et al.
Publicado: (2016)

Dynamic Changes of Cytokine Profiles and Virological Markers Associated With HBsAg Loss During Peginterferon Alpha-2a Treatment in HBeAg-Positive Chronic Hepatitis B Patients
por: Li, Minghui, et al.
Publicado: (2022)

Effectiveness of entecavir or telbivudine therapy in patients with chronic hepatitis B virus infection pre-treated with interferon compared with de novo therapy with entecavir and telbivudine
por: Cai, Shaohang, et al.
Publicado: (2017)

Evolution of entecavir-resistant hepatitis B virus during entecavir and adefovir dipivoxil combination therapy
por: WANG, YANG, et al.
Publicado: (2016)

Comparison of pegylated interferon monotherapy and de novo pegylated interferon plus tenofovir combination therapy in patients with chronic hepatitis B
por: Zheng, Caixia, et al.
Publicado: (2019)

Early Treatment with Pegylated Interferon Lambda for Covid-19
por: Reis, Gilmar, et al.
Publicado: (2023)

Nomogram for evaluating obvious liver inflammation in treatment-naïve HBeAg positive chronic hepatitis B virus infection patients with normal ALT
por: Zhang, Lu, et al.
Publicado: (2023)

Using machine learning models to predict HBeAg seroconversion in CHB patients receiving pegylated interferon‐α monotherapy
por: Shang, Hongyan, et al.
Publicado: (2022)

Novel Pegylated Interferon for the Treatment of Chronic Viral Hepatitis
por: Huang, Yi-Wen, et al.
Publicado: (2022)

Entecavir-associated thrombocytopenia
por: Yu, Yi, et al.
Publicado: (2021)

Mode of regulation of natural killer cell activity by interferon
por: Minato, N, et al.
Publicado: (1980)

Effect of Antiviral Therapy During Pregnancy on Natural Killer Cells in Pregnant Women With Chronic HBV Infection
por: Wang, Fuchuan, et al.
Publicado: (2022)

Retreatment of Patients Nonresponsive to Pegylated Interferon and Ribavirin with Daily High-Dose Consensus Interferon
por: Meyer, Douglas F., et al.
Publicado: (2010)

Comparable efficacy with entecavir monotherapy and tenofovir–entecavir combination in chronic hepatitis B patients
por: Baqai, Sumbella, et al.
Publicado: (2015)

Extensive psoriasis induced by pegylated interferon: a case report
por: Citro, Vincenzo, et al.
Publicado: (2007)

Cannot write session to /tmp/vufind_sessions/sess_ot2es5101mb8pna79ekt52jhlm